Donepezil for behavioural disorders associated with Lewy bodies: A case series

Dementia with Lewy bodies (DLB) has been associated with important behaviou ral disturbances, such as psychotic symptoms. Unfortunately, neuroleptic se nsitivity in these patients limits effective pharmacological management of these symptoms. Seven patients, five male and two female (mean age 75.3 +/- 4.7 years, range 68-81), diagnosed with DLB were treated with the acetylch olinesterase inhibitor donepezil (5-10 mg once daily) to determine its effe ct on treating behavioural disorders. Although the intended length of treat ment was a minimum of 8 weeks, only three patients completed 8 weeks of the rapy, one patient completed 6 weeks, two patients completed 4 weeks and one patient was discontinued after 5 days. The primary outcome (behavioural di sturbances) was measured prospectively by the Neuropsychiatric Inventory (N PI), while other outcomes included cognition (Mini-Mental State Examination (MMSE)) and Clinical Global Impression. Three of the seven subjects showed marked improvement in behaviour, with NPI scores dropping significantly ov er time. Donepezil therapy was discontinued prematurely in three of the cas es due to insufficient response and/or adverse events. Overall, five of the seven patients were rated at least minimally improved in behavioural sympt oms. Our experience with donepezil in this group of patients shows promise. Given the limited experience with this agent in treating behavioural disor ders associated with DLB, further studies are warranted. Copyright (C) 2000 John Wiley & Sons, Ltd.